Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2013

01-12-2013 | Short Research Report

Epidemiology of chemotherapy-induced neutropenia at a tertiary university hospital in Oman

Authors: Maram Abou Saleh, Rose Ngozi Mafiana, Mohammed Al Za’abi, Ragini Vaishnav, Salam Al Kindi, Ibrahim Al-Zakwani

Published in: International Journal of Clinical Pharmacy | Issue 6/2013

Login to get access

Abstract

Background Little is known about the incidence and burden of chemotherapy-induced neutropenia (CIN) in Oman or the Arabian Gulf. Objectives To determine the epidemiology of CIN at Sultan Qaboos University Hospital in Oman. Methods A retrospective observational study of all eligible CIN episodes in adult (>18 years) patients with solid tumors and hematological malignancies at Sultan Qaboos University Hospital (SQUH) from January to December 2010. Analyses were performed using univariate statistics. Results A total of 1,357 episodes in 159 patients with a mean age of 50 ± 15 years (19–91) were evaluated. Fifty-four percent (n = 86) of the patients were female. A total of 46 % (73/159) of the patients developed CIN accounting for 15 % (210/1,357) of all episodes. Twelve percent (25/210) of these CIN episodes were associated with fever in 26 % (19/73) patients. There was significant association between CIN and chemotherapy regimen (P < 0.001), younger age (P < 0.001), low hemoglobin (Hb) levels (P < 0.001) and advanced cancer stage (P = 0.006). Conclusions This study suggests a high incidence of CIN in SQUH patients which resulted in chemotherapy delays, longer hospital stays, and inpatient mortality. CIN was significantly correlated with chemotherapy regimen, younger age, low Hb levels and cancer stage.
Literature
1.
go back to reference National Comprehensive Cancer Network (NCCN), 2013. Guidelines for prevention and treatment of cancer-related infections. Accessed 18 Aug 2013. National Comprehensive Cancer Network (NCCN), 2013. Guidelines for prevention and treatment of cancer-related infections. Accessed 18 Aug 2013.
2.
go back to reference Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730–51.PubMedCrossRef Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730–51.PubMedCrossRef
3.
go back to reference Bow EJ. Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. J Antimicrob Chemother. 1998;41 Suppl D(90004):1–5. Bow EJ. Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. J Antimicrob Chemother. 1998;41 Suppl D(90004):1–5.
4.
go back to reference Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte-colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung-cancer. N Eng J Med. 1991;325(3):164–70.CrossRef Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte-colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung-cancer. N Eng J Med. 1991;325(3):164–70.CrossRef
5.
go back to reference Al-Bahar S, Pandita R, Dhabhar B, Al-Bahar E. Febrile neutropenia in cancer patients in Kuwait: microbial spectrum and outcome. Support Care Cancer. 1994;2(6):400–2.PubMedCrossRef Al-Bahar S, Pandita R, Dhabhar B, Al-Bahar E. Febrile neutropenia in cancer patients in Kuwait: microbial spectrum and outcome. Support Care Cancer. 1994;2(6):400–2.PubMedCrossRef
6.
go back to reference Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med. 1994;121(7):492–501.PubMedCrossRef Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med. 1994;121(7):492–501.PubMedCrossRef
7.
go back to reference Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66.PubMedCrossRef Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66.PubMedCrossRef
8.
go back to reference Krell D, Jones AL. Impact of effective prevention and management of febrile neutropenia. Br J Cancer. 2009;101(Suppl 1):S23–6.PubMedCrossRef Krell D, Jones AL. Impact of effective prevention and management of febrile neutropenia. Br J Cancer. 2009;101(Suppl 1):S23–6.PubMedCrossRef
9.
go back to reference Wilson-Royalty M, Lawless G, Palmer C, Brown R. Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature. J Oncol Pharm Pract. 2002;7(4):141–7.CrossRef Wilson-Royalty M, Lawless G, Palmer C, Brown R. Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature. J Oncol Pharm Pract. 2002;7(4):141–7.CrossRef
Metadata
Title
Epidemiology of chemotherapy-induced neutropenia at a tertiary university hospital in Oman
Authors
Maram Abou Saleh
Rose Ngozi Mafiana
Mohammed Al Za’abi
Ragini Vaishnav
Salam Al Kindi
Ibrahim Al-Zakwani
Publication date
01-12-2013
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2013
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-013-9859-8

Other articles of this Issue 6/2013

International Journal of Clinical Pharmacy 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.